Treatment of urinary tract infection
Reading File
Now I'll search the medical library and PubMed simultaneously for UTI treatment.
Finding Sources
Searching PubMed
"urinary tract infection" AND treatment
Good results. Let me now read the relevant textbook sections and search for more specific content in parallel.
Finding Sources
Reading File
Excellent textbook data retrieved. Now let me get the Goldman-Cecil Medicine UTI treatment section and the inpatient management table.
Finding Sources
Reading File
Reading File
Reading File
Let me get the Cecil Medicine treatment section and special populations content.
Reading File
I now have comprehensive data. Let me compile the full answer.
Treatment of Urinary Tract Infection (UTI)
Classification (Determines Treatment Approach)
UTIs are classified into:
- Uncomplicated - occurs in healthy women with normal genitourinary tracts
- Complicated - associated with structural/functional abnormalities, catheters, pregnancy, immunosuppression, male sex, diabetes, or renal disease (see host factors table below)
- Recurrent - >2 UTIs in 6 months or >3 UTIs in 12 months
- Asymptomatic bacteriuria - colonization without symptoms; only treat in specific circumstances (pregnancy, pre-urologic procedures)
Host factors for complicated UTI:
- Obstruction (strictures, tumor, BPH, stones)
- Functional (neurogenic bladder, vesicoureteral reflux, pregnancy)
- Urologic interventions (catheters, stents, cystoscopy)
- Metabolic/congenital disease
- Immunologic abnormalities (transplant)
Common Pathogens
E. coli is responsible for 75-90% of uncomplicated UTIs. Other pathogens include Staphylococcus saprophyticus, Klebsiella, Proteus, Enterococcus, and Pseudomonas (in complicated/nosocomial cases).
1. Uncomplicated Cystitis (Adult Women)
No initial urine culture is required for straightforward uncomplicated cystitis. Consider local resistance patterns - if resistance is ≥20%, use an alternative agent.
| Drug | Regimen | Notes |
|---|---|---|
| Nitrofurantoin monohydrate/macrocrystals | 100 mg twice daily × 5 days | First-line; not effective in pyelonephritis |
| TMP-SMX DS (160/800 mg) | 1 tab twice daily × 3 days | Avoid if local resistance >20% |
| Fosfomycin | 3 g single dose | Convenient; lower efficacy than others for early pyelonephritis |
| Pivmecillinam | 400 mg twice daily × 5 days | Where available; lower efficacy than some agents |
Fluoroquinolones should be reserved for important uses other than uncomplicated cystitis, due to resistance and adverse effect concerns.
Beta-lactams (amoxicillin-clavulanate, cefpodoxime, cefdinir, cefaclor in 3-7 day regimens) are appropriate when first-line agents cannot be used.
2. Outpatient Pyelonephritis / Complicated UTI
Urine culture is advised. Treat for at least 7 days (mild) to 14 days (severe/clear pyelonephritis). Admit if significantly ill, unable to retain fluids or medications, or pregnant. Consider an IV dose of ceftriaxone if sensitivities are uncertain.
| Drug | Regimen |
|---|---|
| Ciprofloxacin | 500 mg twice daily × 5-7 days |
| Levofloxacin | 750 mg once daily × 5-7 days |
| TMP-SMX DS | 1 tab twice daily × 14 days (only if susceptibility known) |
| Amoxicillin-clavulanate | 875/125 mg twice daily |
| Cefpodoxime | 400 mg twice daily × 7-14 days |
3. Inpatient Management - Pyelonephritis / Complicated UTI
Empiric IV options (from Tintinalli's Emergency Medicine):
| Drug | Dose |
|---|---|
| Ciprofloxacin | 400 mg IV every 12 h |
| Ceftriaxone | 1-2 g IV once daily |
| Cefotaxime | 1-2 g IV every 8 h |
| Gentamicin or tobramycin | 3 mg/kg/day ± ampicillin 2 g q6h |
| Piperacillin-tazobactam | 3.375 g IV every 6 h |
| Cefepime | 1-2 g IV every 8 h |
| Ertapenem | 1 g IV daily |
| Meropenem/Imipenem | 1 g q8h / 500 mg q8h (for MDR) |
After clinical improvement with IV antibiotics, step down to oral agents based on culture sensitivities. Total duration: 7-14 days for most; 21 days for urosepsis.
4. Special Situations
UTI in Men
Any UTI in a young man should be assumed complicated until proven otherwise. Treat 7-14 days; fluoroquinolones are preferred due to prostate penetration. Men without immunocompromise may do well with 7 days rather than 14.
Pregnancy
- Safe agents: nitrofurantoin (avoid near term - risk of neonatal hemolysis), beta-lactams (amoxicillin, cephalosporins), fosfomycin
- Avoid: fluoroquinolones, tetracyclines, TMP-SMX in first trimester and near term
- Treat asymptomatic bacteriuria in pregnancy (unlike non-pregnant patients)
- Screen at first prenatal visit
Catheter-Associated UTI (CAUTI)
- Replace or remove the catheter before collecting cultures and initiating antibiotics
- Treat symptomatic CAUTI for 7-14 days
- Do not treat asymptomatic bacteriuria in catheterized patients
Recurrent UTI
- Culture all patients; treat empirically with uncomplicated cystitis regimens
- Relapses (same organism within 30 days): use an alternative agent from complicated UTI regimens
- Prophylaxis options: continuous low-dose antibiotics, postcoital antibiotics, or patient-initiated self-treatment
Urosepsis
- Broad-spectrum IV antibiotics immediately; follow sepsis bundle
- Early imaging (CT with contrast) to identify source and obstruction
- Blood cultures before starting antibiotics
- Total treatment: up to 21 days
5. Asymptomatic Bacteriuria
Do NOT treat in most patients (including elderly, diabetics, catheterized patients) - treatment increases adverse effects and resistance without benefit.
Treat only in:
- Pregnant women
- Patients undergoing urologic procedures with mucosal disruption
Recent Evidence Updates
Key recent publications worth noting:
- WikiGuidelines 2024 Consensus (PMID 39495518) - comprehensive guidelines for UTI prevention, diagnosis, and management across pediatric and adult populations (JAMA Network Open, 2024)
- Short vs. Long antibiotic courses for pyelonephritis (PMID 40228579) - 2025 living meta-analysis supporting shorter antibiotic durations for pyelonephritis and complicated UTI; watch for updates to duration recommendations
- Catheter replacement in CAUTI (PMID 38916643) - systematic review on catheter replacement practices
Sources: Tintinalli's Emergency Medicine (9e), pp. 620-625 | Goldman-Cecil Medicine (International ed.), Chapter 263 | Harriet Lane Handbook (23e)
This is a shared conversation. Sign in to Orris to start your own chat.